(1)

In the autumn of 1976, a young German scientist and his wife stepped off a plane in Philadelphia, having traveled a very long way to find out what they are capable of. Meenhard Herlyn had earned his doctorate in veterinary medicine from the University of Veterinary Medicine in Hanover and then a second doctorate in medical microbiology from the University of Munich, neither of them obviously implying his future success in melanoma research. His wife, Dorothee, was an immunologist by training, and in the quiet way she would become one of his most important scientific collaborators.

They had come to join The Wistar Institute, one of the oldest independent biological research institutions in the United States, at the invitation of its director, Dr. Hilary Koprowski, a scientist of enormous range and charisma who had spent his career at the crossroads of virology, immunology, and cancer biology. Koprowski was then pressing his laboratory into the emerging territory of monoclonal antibodies. This technology had been described only the year before by Köhler and Milstein in a brief paper in Nature, immediately electrifying the biological world. The concept was seductively simple: fuse an antibody-producing immune cell with an immortal cancer cell to generate an unlimited supply of a single, perfectly specific antibody. It could carry therapeutic payloads straight to the heart of the disease, or the magic bullets killing only cancer cells.

Herlyn arrived at Wistar as a cell biologist who knew how to grow cells, how to ask clean questions in culture, how to build an experiment that the data could actually answer. Koprowski put him to work developing monoclonal antibodies against human cancers. Because the laboratory happened to have some melanoma cell lines already in the freezers, melanoma became his entry point almost by accident. He would later reflect, with the dry humor of a man who had made peace with contingency, that he had not chosen melanoma so much as melanoma had chosen him.

The destiny would develop into a grand foundation in the coming decades. The turning point came through a meeting that Hilary Koprowski arranged — a meeting with a man named Wallace Clark.

By the mid-1970s, Clark was already legendary in the world of dermatopathology. Working first at Harvard and Massachusetts General Hospital, and later at Temple University and the University of Pennsylvania, he had spent years doing something that seemed obvious in retrospect but had required real genius to execute: looking very carefully at melanomas under a microscope, not merely describing the tumor as malignant or benign, but also where it was. He understood melanoma not from a snap shot, but the journey taken by cells through the architecture of the skin.

In 1967, Clark published his histogenetic classification of melanoma. By 1969, refined with colleagues including Martin Mihm, the classification described melanoma with distinct, ordered stages: benign nevi — ordinary moles, stable and largely harmless; dysplastic nevi (moles with atypical features) that might be early warnings; radial growth phase (RGP) primary melanomas, which spread laterally within the epidermis and had not yet demonstrated the will to go deeper; vertical growth phase (VGP) primary melanomas, which had invaded downward into the dermis; and finally metastatic melanoma, which had escaped the skin entirely and colonized distant organs. Each stage had its own histological signature, its own prognostic weight, its own relationship to survival.

Clark was not merely a classifier. He was, as Herlyn would later describe him, "a spiritual mentor who basically showed us the way to the disease." He had what Herlyn called a charismatic approach, the ability to see a stained tissue section as the act of cells. He could translate what he saw in the microscope into the biological logic of living cells and disease conditions. When Koprowski brought him into contact with Herlyn, Clark gave the cell biologist something that the most elegant monoclonal antibody experiments could not provide on their own: a framework. If Clark's stages were real, the biological differences between a radial growth phase melanoma and a metastatic melanoma were not merely a matter of degree, but of kind — then those differences ought to be detectable in living cells, so could be studied, and eventually be intervened. 

Herlyn saw this with the clarity in his head. The  existing tools of melanoma research at that time were not only very few — the Cloudman S91 mouse melanoma, the B16 mouse melanoma line, even the handful of human melanoma lines like SK-MEL-1 that Memorial Sloan Kettering had produced — but also exhibited severe limits. The available mouse melanomas were very different from human melanomas. Cell lines derived exclusively from metastatic deposits, and you could not understand a journey by studying only its destination.

What was needed was a living map.

(2)

The work began with patience. Herlyn established relationships with the clinical surgeons and dermatologists at the University of Pennsylvania who were removing melanocytic lesions from patients, including biopsies of nevi, excisions of primary melanomas at different stages, resections of metastatic lymph nodes and distant deposits. He took each specimen, dissociating the tissue into single cells, and attempting to coax those cells into growing in culture. This was harder than it sounded. Human tumor cells are frequently reluctant in vitro. They carry chromosomal damage, growth dependencies, and environmental demands that bear no resemblance to the sterile plastic world of a tissue culture flask. Many attempts failed, but some took hold.

When a melanoma cell line was established and grew, Herlyn and his colleagues characterized it exhaustively. They looked at its morphology under the microscope — was it epithelioid, spindle-shaped, dendritic? They measured its growth rate, its doubling time, its response to different culture media. They tested whether it required growth factors added from outside or whether it would proliferate in their absence. They injected cells into immunodeficient nude mice and watched to see whether tumors formed, and if so, how quickly and aggressively. They probed the cells with the monoclonal antibodies that the Koprowski laboratory was producing against melanoma surface antigens, mapping patterns of antigen expression across the different line types.

The cells told consistent stories. Cells derived from primary melanoma at radial growth phase, the early, laterally spreading lesions, behaved in culture like cells that were still partially tethered to their tissue of origin. They required exogenous growth factors to proliferate and grew slowly. When injected into nude mice, they were typically non-tumorigenic or only weakly so. They retained the social constraints of normal tissue biology: they needed to be told to grow.

Cells from vertical growth phase primaries behaved differently. They grew somewhat faster, showed increasing indifference to the growth factor requirements that constrained their RGP counterparts, and began to demonstrate the increased ability to form tumors in animals.

And cells from metastatic deposits were like a different breed. They proliferated without waiting for permission. They grew in serum-free conditions, in media stripped of the growth factors that normal melanocytes and RGP cells required absolutely. They formed tumors in nude mice with aggressive efficiency. Crucially, Ulrich Rodeck in Herlyn's group demonstrated in 1987 that metastatic melanoma cell lines — but not primary melanoma lines — could grow in vitro completely independently of exogenous growth factors. Here was a cardinal biological distinction made measurable in a flask: the transition from growth factor dependence to growth factor autonomy was a hallmark of malignant progression, observable directly in the cells of the staging system that Clark had drawn from the microscope.

The collection grew. A line called WM35, derived from a radial growth phase primary tumor, became a prototype for that stage. WM115, from a vertical growth phase primary, became another anchor. From the same patient who had contributed WM115, the surgeons later removed metastatic lymph nodes, and from these came WM239A, WM165-1, and WM266-4 — three independent metastatic lines from the same individual, differing from each other and from the primary in their biological properties, offering a window into the heterogeneity that develops even within a single patient's disease. In this one patient's tumor history, Herlyn had an almost perfect natural experiment: the same genome, the same host, the same environmental history, however cells had diverged during the journey from primary invasion to distant spread.

Dozens of lines followed, and then scores, and eventually more than a hundred, covering the full clinical spectrum of Clark's stages. Each was characterized, catalogued, and made available to other researchers. Herlyn insisted on this. A cell line kept in a single laboratory was a resource; a cell line shared with the world was a foundation. He would distribute the Wistar Melanoma lines freely to any legitimate research group that requested them, and the WM collection would eventually be used in hundreds of laboratories on six continents.

(3)

While Herlyn was building his collection in Philadelphia, a scientist at Yale University School of Medicine was working on a problem that was, at first glance, straightforward. Ruth Halaban wanted to know what a melanocyte actually needed to stay alive.

The question was asked for a practical reason. Normal human melanocytes, comprising only three to seven percent of cells in the epidermis, had resisted reliable culture in vitro for decades. Isolated from skin, they were quickly overwhelmed by the far more numerous keratinocytes and fibroblasts sharing the culture dish. The breakthrough happened in 1982, when Eisinger and Marko added TPA (a phorbol ester) and cholera toxin into the culture. TPA simultaneously suppressed keratinocyte growth and stimulated melanocyte proliferation, and cholera toxin induced cAMP level. This receipt had finally made pure melanocyte cultures reproducible. However, TPA was a tumor promoter, biologically disruptive in ways that made it an imperfect research tool, and the cultures it produced raised immediate questions: were these truly normal melanocytes, or cells already subtly altered by the pharmacological conditions needed to grow them? Halaban wanted to find culture conditions that were not just permissive but physiologically meaningful, i.e. conditions that reflected what actually happened in living skin.

She began taking apart the recipe, ingredient by ingredient, asking what each component was actually doing and whether a more physiologically meaningful substitute could be found. Working with colleagues at Yale and in collaboration with Andrew Baird and the Salk Institute, she identified the specific mitogen that normal melanocytes depended upon for survival in vitro: basic fibroblast growth factor (bFGF). Published in In Vitro Cellular and Developmental Biology in 1987, this finding was striking in its precision. Normal melanocytes, unlike virtually every other human cell type that had been studied in culture, would not survive in routine serum-supplemented medium without the addition of bFGF and a cAMP-elevating agent. Remove bFGF, and the cells died. Add it back, and they flourished. The growth factor was not a convenience but a requirement, a dependency encoded in the biology of the melanocyte lineage itself.

Where, in living skin, did this bFGF come from? A year after the first bFGF paper, Halaban and colleagues answered that question with equal precision. Working with co-cultures of melanocytes and keratinocytes, and tracing the molecular identity of keratinocyte-secreted factors with neutralizing antibodies and blocking peptides, they showed that keratinocytes produce bFGF and deliver it to neighboring melanocytes through a paracrine mechanism. When melanocytes were cultured with keratinocytes, they survived for weeks without added exogenous bFGF, since the keratinocytes were supplying it naturally. Normal melanocytes in living skin, the data showed, are not autonomous cells. They are dependent cells, kept alive and controlled by the tissue around them, recipients of a chemical message — you may grow here — that keratinocytes deliver through their production of bFGF.

This was already an important result. But Halaban's next observation transformed it into something with profound implications for melanoma biology. When she examined melanoma cells — lines derived from metastatic deposits, lines that required no special additives to grow vigorously in standard medium — she found that they produced bFGF themselves. They had internalized the supply chain. The paracrine dependency that kept normal melanocytes tethered to their keratinocyte neighbors, functioned as a biological restraint against uncontrolled proliferation, had been abolished in melanoma cells through "autocrine" production (secreted by and acting on self) of the very growth factor they had previously needed to receive from the outside. Published in Oncogene Research in 1988, this finding of bFGF as an autocrine growth factor in human melanomas provided the first clear molecular narrative of how melanocytes escape keratinocyte control.

Halaban did not stop with bFGF. Through the late 1980s and into the 1990s, she systematically mapped the complete signaling landscape of normal melanocyte survival, finding that three major tyrosine kinase receptor systems governed normal melanocyte proliferation and differentiation: the FGF receptor activated by bFGF; the c-Met receptor activated by hepatocyte growth factor (HGF/scatter factor); and c-Kit, activated by mast cell growth factor (stem cell factor). Each pathway could be examined individually by withholding or adding its specific ligand to the carefully controlled culture medium she had developed. In work published in Oncogene in 1992, she showed that HGF/SF not only stimulated melanocyte proliferation but, remarkably, on its own promoted the motility of normal human melanocytes — the very property that, in the context of melanoma, enabled cells to invade and metastasize. And in work on the c-Kit pathway, she and Funasaka and colleagues demonstrated that c-Kit was robustly expressed on normal human melanocytes and triggered a cascade of intracellular tyrosine phosphorylation in response to mast cell growth factor, but was consistently downregulated in human melanoma cells. The receptor that governed a critical survival pathway in normal melanocytes had been silenced as the disease progressed, replaced by the autonomous signaling loops that the malignant cells had substituted for it.

These findings did more than advance knowledge of melanocyte biology. They solved the culture problem that had frustrated the entire field. Once you knew precisely what normal melanocytes required — bFGF, cAMP-elevating signals, stem cell factor, and HGF, etc. in the proper combinations — you could design culture media that supported not just growth but the physiologically authentic behavior of the cells. And once understanding the signaling requirements of normal melanocytes, you could ask what happened to each requirement at different stages of melanoma progression: which signals were lost, which were internalized as autocrine loops, which receptors were downregulated, which were amplified. The culture medium was not just a tool for keeping cells alive; it was a precision instrument for interrogating the biology of transformation.

This precision translated directly into the ability to establish human melanoma cell lines from clinical specimens that had previously been unculturable. Like Herlyn's experiences, primary melanoma cells, particularly those from early-stage, radial growth phase tumors, were notoriously difficult to maintain in vitro under standard conditions. Halaban's deconstruction of melanocyte signaling requirements pointed toward customized, intermediate culture conditions that could support these transitional cells. This approach, combining Halaban's knowledge of signaling requirements with Herlyn's systematic collection of stage-specific specimens, made it possible to establish cell lines from tumor stages that had resisted in vitro culture using earlier methods.

Together, Halaban's culture biochemistry and Herlyn's clinical specimen collection formed a scientific partnership of complementary precision. Herlyn provided the biological framework from  Clark's stages and the clinical access to specimens at each stage. Halaban provided the biochemistry of what signals each stage needed, and how to supply them artificially. The result was a collection of human melanoma cell lines that represented the full biological progression of the disease, growing in conditions calibrated to the specific signaling state of each stage, and therefore capable of answering biological questions that no previous model had been able to address.

(4)

While Herlyn and Halaban were delineating the culture condition and signaling factors required for maintenance of melanoma cells and melanocyte in vitro, at the other side of Atlantic, a scientist at St. George's Hospital Medical School in London was investigating the same territory from a different direction entirely: what genetic decisions governed whether they lived, arrested, or became immortal.

Dorothy "Dot" Bennett had begun her career studying pigmentation genetics in murine melanocytes, and her first major contribution to the field's shared toolkit came in 1987 with the creation of Melan-a, the first non-tumorigenic, immortal line of pigmented mouse melanocytes, derived from C57BL/6 embryos. Before 1980s, B16 cell line, which was derived from a melanoma spontaneously occurred also in a C57BL/6 mouse, was almost the only choice for studying melanoma. Even after the development of many other melanoma cell lines, including those derived from mouse and human melanoma, B16 cell line is still one of the most important reagents in melanoma research today. Before Melan-a, researchers wishing to compare a normal melanocyte and a melanoma cell in the same genetic background had no stable, well-characterized normal partner for B16 melanoma line and its sublines. Melan-a cells expressed melanocyte markers and behaved as normal melanocytes in culture — synthesizing melanin, responding to TPA, retaining normal morphology while being sufficiently stable and proliferative for genetic manipulation. They immediately became a reference standard used by laboratories across the field. Herlyn's team used them alongside the WM series, and Halaban's team performed gain-of-function and loss-of-function experiments on the bFGF signaling axis.

The key experiment performed by Halaban and teams with Melan-a cells illustrates how directly Bennett's tools fed into the signaling story. In 1989, Dotto, Moellmann, Ghosh, Edwards, and Halaban retrovirally introduced bFGF cDNA into Melan-a cells to force constitutive bFGF expression — precisely mimicking the autocrine production that Halaban had identified in metastatic human melanoma cells. The result was the acquisition of growth factor–independent proliferation and partial malignant phenotype, directly confirming that bFGF autocrine production was not simply a marker of transformation but a causal contributor to it. The experiment was only possible because Melan-a provided a stable, manipulable murine normal melanocyte recipient. Bennett's cell biology had made Halaban's signaling hypothesis experimentally testable.

But Bennett's most consequential contribution to the shared framework was not a cell line. It was a model explaining why the melanoma journey happened at all, and why it happened in the sequence that it did. Through a combination of retroviral gene transfer and culture experiments in the early 2000s, Bennett and her collaborators tried to explore which gene or its disruption could turn normal melanocytes to melanoma cells.  From this they constructed a four-stage genetic model of melanoma initiation and progression: first, an oncogenic driver mutation such as BRAF V600E in a single melanocyte, stimulating proliferation and producing a growing nevus; second, the triggering of oncogene-induced senescence by the same BRAF mutation, arresting the nevus cells in a permanent growth arrest mediated by p16; third, in a rare cell, the loss of p16 or other senescence-pathway effectors, enabling escape from the arrest and the initiation of invasive growth; and fourth, the acquisition of telomerase activity and full immortalization, enabling unlimited replication and metastatic potential.

This model was an illumination of Herlyn's staged progression system from the inside. Clark had described the stages from the microscope; Herlyn had built them in culture; Bennett now explained the genetic switches that governed the transitions between them. For example, the RGP cells in Herlyn's collection were cells that had not yet completed immortalization and showed transitional behavior. The metastatic WM lines had completed the senescence-escape sequence. The difficulty of establishing early-stage cultures was not merely a technical obstacle but a biological truth about where those cells were in the senescence-immortalization continuum.

Bennett's model also enriched the interpretation of Halaban's signaling data. Halaban had shown that the acquisition of bFGF autocrine production was a feature of advanced, growth factor–independent disease. A melanocyte losing p16 might become senescence-resistant without immediately producing bFGF autonomously; or p16 loss might enable the epigenetic changes that allowed bFGF to be expressed; or the two might occur in parallel through different selective pressures. The resolution of this relationship — which Bennett and Halaban each approached from their respective angles without fully converging — drove research forward in both directions and more understanding of the molecular events required for full malignant transformation.

By the late 1980s and into the 1990s, the three independent research programs interwound to form the foundation of experimental melanoma research. Herlyn's cell lines provided the progression-stage resolution that gave the experiments their biological meaning. Bennett's kinase discovery approach provided the breadth of molecular survey that neither a targeted signaling study nor an untargeted screen could have achieved alone. And Halaban's signaling framework was the key axes governing normal and malignant melanocyte behavior, provided the interpretive context that made the kinase expression patterns legible. What sustained this triangle across decades was not institutional connection, but shared scientific purpose, shared tools, and the mutual recognition that each program's questions kept intersecting with the others' answers. Rather than holding the materials for their own research, they sent the cell lines, reagents, and precise description of methods ("protocols" in the academic jargon) to anyone who wanted to investigate melanoma nationwide and worldwide. With the dissemination of these materials and methods, the triangle forces built the foundation of experimental melanoma research.